Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results

BACKGROUND: Relugolix is a once-daily, oral, nonpeptide, gonadotropin-releasing hormone receptor antagonist. The aim of this study was to evaluate safety of relugolix over 24 weeks in women with endometriosis-associated pain. METHODS: This phase 2, randomized, open-label, parallel-group extension st...

Descripción completa

Detalles Bibliográficos
Autores principales: Osuga, Yutaka, Seki, Yoshifumi, Tanimoto, Masataka, Kusumoto, Takeru, Kudou, Kentarou, Terakawa, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218467/
https://www.ncbi.nlm.nih.gov/pubmed/34154590
http://dx.doi.org/10.1186/s12905-021-01393-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218467/
https://www.ncbi.nlm.nih.gov/pubmed/34154590
http://dx.doi.org/10.1186/s12905-021-01393-3

Ejemplares similares